These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://haimaorsw543305.myparisblog.com/39701491/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide